Analysts Set Audentes Therapeutics (BOLD) Price Target at $35.43

Shares of Audentes Therapeutics (NASDAQ:BOLD) have received an average recommendation of “Buy” from the thirteen research firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $35.43.

A number of equities analysts recently commented on BOLD shares. BidaskClub cut shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 15th. HC Wainwright set a $37.00 price objective on shares of Audentes Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Mizuho started coverage on shares of Audentes Therapeutics in a research report on Monday, February 12th. They issued a “neutral” rating and a $26.00 price objective on the stock. Finally, William Blair restated a “buy” rating on shares of Audentes Therapeutics in a research report on Friday, March 9th.

NASDAQ:BOLD traded up $2.44 during trading hours on Friday, reaching $37.98. The company’s stock had a trading volume of 354,937 shares, compared to its average volume of 430,759. The stock has a market cap of $1,363.18, a PE ratio of -10.71 and a beta of 1.39. Audentes Therapeutics has a 1 year low of $13.90 and a 1 year high of $41.80.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Thursday, March 8th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.09. equities research analysts predict that Audentes Therapeutics will post -3.43 EPS for the current fiscal year.

In other news, VP Suyash Prasad sold 1,900 shares of Audentes Therapeutics stock in a transaction dated Monday, March 26th. The shares were sold at an average price of $30.00, for a total transaction of $57,000.00. Following the sale, the vice president now owns 1,900 shares of the company’s stock, valued at approximately $57,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Orbimed Advisors Llc sold 421,638 shares of Audentes Therapeutics stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $35.17, for a total transaction of $14,829,008.46. The disclosure for this sale can be found here. Insiders sold 1,138,107 shares of company stock worth $39,502,022 in the last 90 days. Corporate insiders own 47.30% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in shares of Audentes Therapeutics during the 3rd quarter valued at about $143,000. Teacher Retirement System of Texas bought a new stake in shares of Audentes Therapeutics during the 4th quarter valued at about $208,000. MetLife Investment Advisors LLC bought a new stake in shares of Audentes Therapeutics during the 4th quarter valued at about $248,000. Virtus Fund Advisers LLC bought a new stake in shares of Audentes Therapeutics during the 4th quarter valued at about $372,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Audentes Therapeutics by 86.1% during the 3rd quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 6,667 shares in the last quarter. 66.96% of the stock is currently owned by hedge funds and other institutional investors.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Critical Comparison: CACI  vs. The Keyw
Critical Comparison: CACI vs. The Keyw
Contrasting Rockwell Automation  & Trimble
Contrasting Rockwell Automation & Trimble
Prime-XI Price Down 23% Over Last Week
Prime-XI Price Down 23% Over Last Week
Playkey  Price Up 40.4% Over Last 7 Days
Playkey Price Up 40.4% Over Last 7 Days
Dalecoin Trading Down 3.7% This Week
Dalecoin Trading Down 3.7% This Week
Lenovo  Announces  Earnings Results
Lenovo Announces Earnings Results


© 2006-2018 Ticker Report. Google+.